X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217579
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-filing-of-an-efficacy-supplement-for-zynrelef-and-provision-in-newly-passed-congressional-bill-anticipated-to-provide-separate-reimbursement-outside-of-the-packaged-surgical-payment-for-zynrelef-301710904.html
https://news.bloomberglaw.com/class-action/recro-pharma-will-pay-1-4-million-under-shareholder-settlement
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-24-2022-1661335123.pdf
https://www.globenewswire.com/news-release/2022/08/22/2502137/0/en/Baudax-Bio-receives-notice-of-allowance-for-U-S-Patent-Application-covering-use-of-ANJESO-for-the-treatment-of-moderate-to-severe-pain.html
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-fda-approval-of-a-significant-indication-expansion-for-zynrelef-301440851.html
https://www.globenewswire.com/news-release/2021/09/14/2296511/33090/en/Axsome-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-for-AXS-07-for-the-Acute-Treatment-of-Migraine.html
https://www.fiercepharma.com/pharma/heron-s-newly-minted-opioid-alternative-for-post-surgical-pain-headed-for-blockbuster-land
https://www.ema.europa.eu/documents/product-information/zynrelef-epar-product-information_en.pdf
http://www.globenewswire.com/news-release/2020/09/24/2098506/0/en/Axsome-Therapeutics-Presents-New-Data-from-MOMENTUM-Phase-3-Trial-with-AXS-07-Demonstrating-Rapid-Onset-of-Action-and-Reduced-Symptom-Recurrence-in-the-Acute-Treatment-of-Migraine.html
https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-announces-successful-outcome-fda-type-meeting#:~:text=(Nasdaq%3A%20HRTX)%2C%20a,FDA)%20in%20which%20alignment%20was
https://www.globenewswire.com/news-release/2020/07/30/2070683/0/en/Baudax-Bio-Announces-Presentation-of-New-Phase-IIIb-ANJESO-Data-at-the-American-Society-of-Colon-and-Rectal-Surgeons-2020-Annual-Scientific-Meeting.html
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
https://www.globenewswire.com/news-release/2020/07/20/2064250/0/en/Baudax-Bio-Secures-Pharmacy-Supplier-Agreement-with-Vizient-Inc-for-ANJESO.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209487
https://www.prnewswire.com/news-releases/heron-therapeutics-announces-publication-of-results-from-study-209-a-phase-2b-study-of-htx-011-in-patients-undergoing-total-knee-arthroplasty-301070514.html
https://www.globenewswire.com/news-release/2020/06/01/2041360/0/en/Baudax-Bio-Secures-50-Million-Credit-Facility.html
https://www.ema.europa.eu/en/news/committee-medicinal-products-veterinary-use-cvmp-meeting-17-18-march-2020
https://www.globenewswire.com/news-release/2020/02/20/1987706/0/en/Axsome-Therapeutics-Completes-Patient-Enrollment-in-the-INTERCEPT-Phase-3-Trial-of-AXS-07-in-the-Early-Treatment-of-Migraine.html
https://www.globenewswire.com/news-release/2019/12/30/1964870/0/en/Axsome-Therapeutics-Announces-AXS-07-Achieves-Co-Primary-and-Key-Secondary-Endpoints-in-MOMENTUM-Phase-3-Migraine-Trial-in-Patients-with-History-of-Inadequate-Response.html
https://www.globenewswire.com/news-release/2019/10/31/1938619/0/en/FDA-Grants-Appeal-to-Recro-Pharma-for-IV-Meloxicam-New-Drug-Application.html
https://www.contractpharma.com/contents/view_breaking-news/2018-12-26/recro-pharma-amends-iv-meloxicam-license-agreement-with-alkermes/9778
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211398
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003018.jsp&mid=WC0b01ac058004d5c1
https://www.pharmacompass.com/pdf/news/vivlodex-brand-meloxicam-iceutica-v-novitium-pharma-1525071504.pdf
https://www.prnewswire.com/news-releases/mylan-to-leverage-its-world-class-scientific-platform-to-develop-a-novel-delivery-for-meloxicam-a-non-opioid-pain-medication-300628248.html
https://www.reuters.com/article/us-health-nsaids-overdosing/many-people-take-dangerously-high-amounts-of-ibuprofen-idUSKBN1FS336
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-18-2017-1508294527.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-vivlodex-meloxicam-capsules-1496816342.pdf
https://www.pharmacompass.com/pdf/news/ceva-sante-animale-zeleris-florfenicol-meloxicam-receives-approval-in-europe-1496838561.pdf
http://www.prnewswire.com/news-releases/iroko-pharmaceuticals-announces-key-patent-for-vivlodex-300387026.html
https://globenewswire.com/news-release/2016/11/28/893043/0/en/Recro-Pharma-Reports-Positive-Top-Line-Results-from-Pivotal-Phase-III-Clinical-Trial-of-IV-Meloxicam.html
http://www.pharma-excipients.ch/2016/05/31/new-multi-particle-systems-for-colon-targeted-meloxicam/
http://www.pharma-excipients.ch/2016/03/05/nano-crystalline-cellulose-as-a-novel-tablet-excipient-for-improving-solubility-and-dissolution-of-meloxicam/
http://www.prnewswire.com/news-releases/vivlodex-now-available-in-us-pharmacies-for-the-management-of-osteoarthritis-pain-300220385.html
http://www.reuters.com/article/us-recro-pharma-inc-study-idUSKBN0UK1JH20160106
Market Place
Share 
